Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02349789 · ClinicalTrials.gov registry record

The Role of Cerebellar Hyperactivity in Parkinson's Disease

A clinical trial, sponsored by Hugo W. Moser Research Institute at Kennedy Krieger.

Completed
Registry status
11
Enrollment target

NCT02349789 is a clinical trial that has completed, run by Hugo W. Moser Research Institute at Kennedy Krieger. The registered enrollment target is 11 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02349789 has completed, sponsored by Hugo W. Moser Research Institute at Kennedy Krieger.

COMPLETED
Registry status
11 participants
Enrollment target

Study Summary

Gait and balance disturbances are one of the most incapacitating symptoms of Parkinson's disease (PD) (Boonstra et al. 2008). They can cause falls and are therefore associated with the negative spiral of (near) falls, fear of falling, fractures, reduced mobility and social isolation; hence, having a profound negative impact on quality of life (Lin et al. 2012). Originally, symptoms of PD were ascribed to dopamine deficiency and basal ganglia dysfunction (Wu et al. 2013). However, in the last decades it has become clear that other brain structures are also involved in the pathophysiology of PD (Snijders et al. 2011; Stefani et al. 2007). An intriguing, emerging insight is that the cerebellum may be involved in the pathophysiology of PD (Wu et al. 2013). That is, the cerebellum is hyperactive in PD patients during different motor tasks (Yu et al. 2007; Hanakawa et al. 1999; del Olmo et al. 2006). However, whether cerebellar hyperactivity is pathological or compensatory and how it affects gait and balance in PD patients remain open questions. Here, the investigators aim to elucidate the role of the hyperactive cerebellum in gait dysfunction in PD patients by modulating cerebellar excitability with state-of-the-art non-invasive brain stimulation techniques and investigate the effects on gait.

Trial Details

FieldValue
Enrollment Target 11 participants
Start Date 2015-01-28
Est. Completion 2017-09

What the Registry Record Tells You About NCT02349789

The ClinicalTrials.gov registry entry for NCT02349789 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hugo W. Moser Research Institute at Kennedy Krieger, which has 73 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 0 interventions.

NCT02349789 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02349789 about?

NCT02349789 is a clinical study titled "The Role of Cerebellar Hyperactivity in Parkinson's Disease". Gait and balance disturbances are one of the most incapacitating symptoms of Parkinson's disease (PD) (Boonstra et al. 2008). They can cause falls and are therefore associated with the negative spiral of (near) falls, fear of falling, fractures, reduced mobility and social isolation; hence, having a...

What is the current status of trial NCT02349789?

This trial is currently completed. The enrollment target is 11 participants. The study started on 2015-01-28. Estimated completion is 2017-09.

Who is sponsoring clinical trial NCT02349789?

This trial is sponsored by Hugo W. Moser Research Institute at Kennedy Krieger, which has 73 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.